| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Investors with a lot of money to spend have taken a bullish stance on Pfizer (NYSE:PFE).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PFE, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 21 options trades for Pfizer.
This isn't normal.
The overall sentiment of these big-money traders is split between 52% bullish and 38%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $112,000, and 20, calls, for a total amount of $1,115,688.
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $23.0 to $37.5 for Pfizer during the past quarter.
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Pfizer's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Pfizer's significant trades, within a strike price range of $23.0 to $37.5, over the past month.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PFE | CALL | TRADE | BULLISH | 06/18/26 | $7.65 | $7.65 | $7.65 | $23.00 | $153.0K | 392 | 220 |
| PFE | CALL | SWEEP | NEUTRAL | 01/17/25 | $5.25 | $5.0 | $5.1 | $25.00 | $124.4K | 33.2K | 503 |
| PFE | PUT | TRADE | BEARISH | 06/21/24 | $1.13 | $1.09 | $1.12 | $30.00 | $112.0K | 23.3K | 74 |
| PFE | CALL | TRADE | BULLISH | 01/17/25 | $2.0 | $1.95 | $2.0 | $30.00 | $100.0K | 45.5K | 1.7K |
| PFE | CALL | SWEEP | BULLISH | 07/19/24 | $0.76 | $0.73 | $0.76 | $30.00 | $76.0K | 17.1K | 2.8K |
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
After a thorough review of the options trading surrounding Pfizer, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Pfizer, Benzinga Pro gives you real-time options trades alerts.
Posted In: PFE
